314.95 +0.43 (0.14%)
After hours: 7:26PM EDT
|Bid||311.51 x 1200|
|Ask||313.93 x 800|
|Day's Range||314.00 - 322.44|
|52 Week Range||226.62 - 372.61|
|Beta (3Y Monthly)||1.44|
|PE Ratio (TTM)||56.57|
|Earnings Date||Apr 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||340.54|
The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
The gene-sequencing pioneer isn't likely to hit a home run in Q1. But Illumina should run up the score later in 2019.
The United Kingdom's Competition and Markets Authority has opened an investigation into the acquisition. What happens now?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak perf...
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Earlier this week, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted, giving investors a new avenue for tapping the fast-growing genomics market. GNOM tracks the Solactive Genomics Index ...
Illumina Inc. is acquiring Pacific Biosciences for $8 per share in cash. Now trading at just $7.30 a piece, this looks like an attractive arbitrage opportunity
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.
Illumina, Inc. (ILMN) today announced that it will issue results for first quarter 2019 following the close of market on Thursday, April 25, 2019. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Interested parties may access the live teleconference through the Investor Relations section of Illumina’s website under the “company” tab at www.illumina.com.
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...
Illumina Inc NASDAQ/NGS:ILMNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ILMN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ILMN are favorable with net inflows of $113.61 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.